UCB S.A. (UCBJY)
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products...
- Open
- 128.910
- High
- 128.910
- Low
- 127.950
- Prev. Close
- 129.230
- Volume
- 62.82K
- Turnover
- 8.07M
- Avg Price
- 128.407
- Bid/Ask Ratio
- --
- Amplitude
- 0.74%
- 52wk High
- 167.688
- Volume Ratio
- 1.62
- Turnover Ratio
- 0.03%
UCB S.A. Analyst Rating
View moreForecast & Rating
Aug 3, 2026Price forecast
$163.8927.54%
Forecast & RatingStrong buy
2analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 12 hours ago
Antengene says Australia HREC clears Phase 1 ATTRACT trial of ATG-201 in B-cell autoimmune diseases
- PUBT · Aug 21 at 05:27 AM
Antengene FY26 H1 returns to profit at RMB 216.35 million; revenue more than doubled to RMB 513.08 million
- PR Newswire · Aug 16 at 07:05 AM
Axios Names UCB a Winner of the Metro Atlanta Top Workplaces 2026 Award
- Simplywall · Jul 31 at 02:19 PM
UCB (ENXTBR:UCB) Stock Can Profit Momentum Calm Durability Doubts?
- Quartr · Jul 30 at 06:41 AM
UCB: Revenue and net sales grew over 20% YoY, with upgraded 2026 guidance and strong pipeline momentum
- MSN · Jul 30 at 03:22 AM
UCB shares fall despite guidance upgrade as investors question earnings quality
